Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

Cancer Research UK starts phase 1/1b clinical trial of taladegib in combination with paclitaxel Ignyta announced that Cancer Research UK has initiated a new, investigator-sponsored Phase 1/1b clinical trial of a combination of paclitaxel with taladegib - the company's novel, orally available, hedgehog/smoothened inhibitor - in patients with platinum-resistant, recurrent ovarian cancer or recurrent, advanced solid tumors.
Contract Research & Services > Clinical Trials > News
Juventas enrolls first patient in phase 2 gene therapy clinical trial Juventas Therapeutics is enrolling its STOP-PAD trial, a 120-patient, placebo-controlled, randomized double-blinded Phase 2 study evaluating the safety and efficacy of JVS-100, a gene therapy encoding human stromal cell-derived factor-1 (SDF-1), in patients with advanced peripheral artery disease (PAD)
Contract Research & Services > Clinical Trials > News Fast Forward Pharmaceuticals starts phase II trials of FFP104 anti-CD40 monoclonal antibody By PBR Staff Writer
Fast Forward Pharmaceuticals has started two phase II clinical trials in primary biliary cirrhosis (PBC) and Crohn’s disease with its FFP104 anti-CD40 monoclonal antibody.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Cytori Cell Therapy found safe in phase I erectile dysfunction trial
By PBR Staff Writer
The phase I erectile dysfunction trial of Cytori Therapeutics' Cytori Cell Therapy was found to be safe and potentially effective in the European Union.
Contract Research & Services > Clinical Trials > News
Alnylam completes enrollment in APOLLO phase 3 study with Patisiran in rare protein disorder
Alnylam Pharmaceuticals has completed enrollment - with well over 200 patients accrued - in its APOLLO Phase 3 study with patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
Contract Research & Services > Clinical Trials > News
Matinas gets FDA nod to start phase 1 study of MAT2501 to treat NTM infections
Matinas BioPharma has announced that its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) is now open and the Company is authorized to initiate a Phase 1 clinical study for investigational drug, MAT2501 (encochleated amikacin), for the treatment of non-tuberculous mycobacterium (NTM) infections, its lead chronic indication.
Contract Research & Services > Clinical Trials > News
Spectrum Pharmaceuticals starts registrational trial of SPI-2012 in breast cancer
Spectrum Pharmaceuticals has initiated the planned registrational trial for SPI-2012 (eflapegrastim), its novel, long-acting G-CSF.
Contract Research & Services > Clinical Trials > News
RegeneRx completes patient enrollment in phase 2b/3 US dry eye trial
RegeneRx Biopharmaceuticals announced that its US joint venture with G-treeBNT, ReGenTree, has completed enrollment of its Phase 2b/3 dry eye trial in the US.
Contract Research & Services > Clinical Trials > News
AbbVie starts enrollment in phase 3 clinical study for elagolix in patients with uterine fibroids
AbbVie has started the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo.
Contract Research & Services > Clinical Trials > News
Bristol-Myers Squibb's phase 3 Opdivo head and neck cancer study stopped early
Bristol-Myers Squibb announced that a randomized Phase 3 study evaluating Opdivo (nivolumab) versus investigator’s choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) was stopped early because an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its primary endpoint, demonstrating superior overall survival (OS) in patients receiving Opdivo compared to the control arm.
Contract Research & Services > Clinical Trials > News
Rigel completes patient enrollment in first phase 3 study of fostamatinib in ITP
By PBR Staff Writer
Rigel Pharmaceuticals has completed patient enrollment in the first of two phase 3 clinical studies of fostamatinib in immune thrombocytopenic purpura (ITP).
Contract Research & Services > Clinical Trials > News
Genticel unveils initial results of phase 2 trial of GTL001 HPV immunotherapeutic candidate
Genticel has announced initial results from the ongoing randomized, double-blind, placebo controlled phase 2 clinical study of its immunotherapeutic candidate, GTL001, designed to clear HPV 16 and/or 18 infection.
Contract Research & Services > Clinical Trials > News
Stemedica Cell Technologies completes enrollment in phase I/IIa study for ischemic stroke
Stemedica Cell Technologies has completed enrollment into a phase I/IIa, multi-center, open-label study to assess the safety, tolerability, and preliminary efficacy of a single intravenous dose of allogeneic mesenchymal bone marrow cells to subjects with ischemic stroke.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests